演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

大腸癌術後補助CAPOX療法時の有害事象管理の重要性

演題番号 : P17-6

[筆頭演者]
演者)岡野 美穂:1 
[共同演者]
奥山 正樹:1、谷崎 慶子:1、畑 知樹:1、川田 純司:1、金 よう国:1、今本 治彦:1、辻仲 利政:1

1:市立貝塚病院・外科

 

Purpose: According to the results of combined phase III analyses (IDEA collaboration study) comparing durations of adjuvant Oxaliplatin-based therapy (3 vs. 6 months) for patients with colon cancer, adjuvant chemotherapy with OX regimens for 6 month is still standard. When using CAPOX which is one of representative OX regimens, it is important to control adverse events to maintain 6 month compliance of chemotherapy. Since team management was introduced at our hospital to establish early management of adverse events during chemotherapy, the results of adjuvant chemotherapy with CAPOX regarding occurrence of toxicities and compliance of chemotherapy is herein reported. Patients and Methods: From April 2013 to September 2017, total 39 patients were treated with CAPOX as adjuvant chemotherapy. Adverse events were evaluated using toxicity check-sheet by nurses or pharmacists before consultation of physicians. Age; 45-79 year-old (median 67), male: 26, female;3 cases, stage II; 3,IIIa; 20, IIIb; 16cases.Results:Compliance rate of CAPOX for 6 month was 67%.Regarding cycles of OX, 26% patients received 6 cycles, 13% patients 7 cycles and 38% patients 8 cycles. Over 75% patients received over 6 cycles of OX. Neurotoxicity was the main reason for interruption of chemotherapy. G3 or more of non-hematological toxicities were fatigue (3%) and diarrhea (3%). G3 hematological toxicities were observed on 16% of patients while all grades on 49%. All grades of peripheral neurotoxicity were observed on 79% of patients while there was no Grade3 case. Conclusions: Comparing to previous reports, compliance of CAPOX at our institute was relatively high and occurrence of G3 toxicities was low. Because of our team approach, severity of toxicities could be attenuated to improve compliance of adjuvant chemotherapy.

キーワード

臓器別:大腸・小腸

手法別:化学療法

前へ戻る